{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:58:19Z","timestamp":1794697099653,"version":"4.9.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,3,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder, characterized by the presence of BCR\/ABL fusion gene. It is unclear which cellular events drive BCR\/ABL gene translocation or initiate leukemogenesis in CML. Bcl-2 promotes survival of hematopoietic stem cells. Accordingly, apoptosis-related pathway may involve in the leukemogenesis of CML. In the current study, we evaluated 80 single nucleotide polymorphism (SNP) markers involved in the pathways of apoptosis (n = 30), angiogenesis (n = 7), myeloid cell growth (n = 14), xenobiotic metabolism (n = 13), WT1 signaling (n = 7), interferon signaling (n = 4), and others (n = 5) in 170 CML patients and 182 healthy controls. In a single-marker analysis, the following SNPs were identified including VEGFA, BCL2, CASP7, JAK3, CSF3, and HOCT1. In the multivariate logistic model with these SNPs and covariates, only BCL2 (rs1801018) was significantly associated with the susceptibility to CML (P = .05; odds ratio [OR] 2.16 [1.00-4.68]). In haplotype analyses, haplotype block of BCL2 consistently showed significant association with the susceptibility to CML. Risk allele analysis showed that a greater number of risk alleles from BCL2 SNP correlated to increasing risk of CML (overall P = .1, OR 1.84 [1.06-3.22] for 3-4 risk alleles vs 0-1 risk alleles). The current study indicated that BCL2 SNP seemed to be associated with increasing susceptibility to CML.<\/jats:p>","DOI":"10.1182\/blood-2008-07-169110","type":"journal-article","created":{"date-parts":[[2009,1,14]],"date-time":"2009-01-14T02:37:51Z","timestamp":1231900671000},"page":"2517-2525","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia"],"prefix":"10.1182","volume":"113","author":[{"given":"Dong Hwan (Dennis)","family":"Kim","sequence":"first","affiliation":[{"name":"Chronic Myelogenous Leukemia Group, Department of Hematology\/Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON;"},{"name":"Department of Hematology\/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Liu","sequence":"additional","affiliation":[{"name":"Analytical Genetics Technology Centre, University Health Network, Toronto, ON"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Siminovitch","sequence":"additional","affiliation":[{"name":"Analytical Genetics Technology Centre, University Health Network, Toronto, ON"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans A.","family":"Messner","sequence":"additional","affiliation":[{"name":"Chronic Myelogenous Leukemia Group, Department of Hematology\/Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Chronic Myelogenous Leukemia Group, Department of Hematology\/Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111908093817900_B1","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362.421k17_3362_3367","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"key":"2019111908093817900_B2","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"key":"2019111908093817900_B3","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.V83.8.2038.2038","article-title":"Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia.","volume":"83","author":"Bedi","year":"1994","journal-title":"Blood"},{"key":"2019111908093817900_B4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/scbi.2001.0387","article-title":"Molecular evolution of chronic myeloid leukaemia.","volume":"11","author":"Shteper","year":"2001","journal-title":"Semin Cancer Biol"},{"key":"2019111908093817900_B5","doi-asserted-by":"crossref","first-page":"12804","DOI":"10.1073\/pnas.96.22.12804","article-title":"Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.","volume":"96","author":"Jiang","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111908093817900_B6","first-page":"933","article-title":"Mutants of a multipotent hematopoietic cell line blocked in GM-CSF\u2013induced differentiation are leukemogenic in vivo.","volume":"22","author":"Just","year":"1994","journal-title":"Exp Hematol"},{"key":"2019111908093817900_B7","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood.V92.10.3829.422k14_3829_3840","article-title":"Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.","volume":"92","author":"Zhang","year":"1998","journal-title":"Blood"},{"key":"2019111908093817900_B8","first-page":"1218","article-title":"Detection of FLT3 gene and FLT3\/ITD gene mutation in chronic myeloid leukemia and its significance.","volume":"23","author":"Xu","year":"2004","journal-title":"Ai Zheng"},{"key":"2019111908093817900_B9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/10428190400005320","article-title":"Activation of the Jak3 pathway and myeloid differentiation.","volume":"46","author":"Mangan","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"2019111908093817900_B10","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.V100.8.2753","article-title":"Activation of the Jak3 pathway is associated with granulocytic differentiation of myeloid precursor cells.","volume":"100","author":"Rane","year":"2002","journal-title":"Blood"},{"key":"2019111908093817900_B11","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood.V84.9.3142.3142","article-title":"Altered levels of interleukin-1 \u03b2 and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates.","volume":"84","author":"Wetzler","year":"1994","journal-title":"Blood"},{"key":"2019111908093817900_B12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood-2003-08-2695","article-title":"Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia.","volume":"104","author":"Legros","year":"2004","journal-title":"Blood"},{"key":"2019111908093817900_B13","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1182\/blood-2003-08-2734","article-title":"Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.","volume":"103","author":"Kvasnicka","year":"2004","journal-title":"Blood"},{"key":"2019111908093817900_B14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/sj.leu.2402769","article-title":"Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study.","volume":"17","author":"Korkolopoulou","year":"2003","journal-title":"Leukemia"},{"key":"2019111908093817900_B15","first-page":"200","article-title":"Overexpression of MDR-related p170 glycoprotein in chronic myeloid leukemia.","volume":"79","author":"Michelutti","year":"1994","journal-title":"Haematologica"},{"key":"2019111908093817900_B16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1046\/j.1365-2141.1996.273807.x","article-title":"Studies of P-glycoprotein in chronic myelogenous leukaemia patients: expression, activity and correlations with CD34 antigen.","volume":"92","author":"Turkina","year":"1996","journal-title":"Br J Haematol"},{"key":"2019111908093817900_B17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<805::AID-CNCR16>3.0.CO;2-E","article-title":"Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.","volume":"86","author":"Giles","year":"1999","journal-title":"Cancer"},{"key":"2019111908093817900_B18","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate.","volume":"108","author":"Jordanides","year":"2006","journal-title":"Blood"},{"key":"2019111908093817900_B19","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V87.7.2878.bloodjournal8772878","article-title":"Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis.","volume":"87","author":"Yamagami","year":"1996","journal-title":"Blood"},{"key":"2019111908093817900_B20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.leukres.2006.10.016","article-title":"MTHFR 677CC\/1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea.","volume":"31","author":"Moon","year":"2007","journal-title":"Leuk Res"},{"key":"2019111908093817900_B21","doi-asserted-by":"crossref","first-page":"8592","DOI":"10.1158\/1078-0432.CCR-05-0039","article-title":"Two single-nucleotide polymorphisms with linkage disequilibrium in the human programmed cell death 5 gene 5\u2032 regulatory region affect promoter activity and the susceptibility of chronic myelogenous leukemia in Chinese population.","volume":"11","author":"Ma","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2019111908093817900_B22","first-page":"251","article-title":"GSTT1 and GSTM1 deletions, NQO1 C609T polymorphism and risk of chronic myelogenous leukemia in Japanese.","volume":"6","author":"Hishida","year":"2005","journal-title":"Asian Pac J Cancer Prev"},{"key":"2019111908093817900_B23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/j.1460-2075.1994.tb06319.x","article-title":"Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.","volume":"13","author":"Puil","year":"1994","journal-title":"Embo J"},{"key":"2019111908093817900_B24","first-page":"5535","article-title":"Growth factor-mediated terminal differentiation of chronic myeloid leukemia.","volume":"54","author":"Bedi","year":"1994","journal-title":"Cancer Res"},{"key":"2019111908093817900_B25","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome.","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"2019111908093817900_B26","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/j.1460-2075.1990.tb08212.x","article-title":"bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.","volume":"9","author":"Elefanty","year":"1990","journal-title":"EMBO J"},{"key":"2019111908093817900_B27","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL.","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111908093817900_B28","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1073\/pnas.90.8.3755","article-title":"Efficient transplantation of BCR-ABL\u2013induced chronic myelogenous leukemia-like syndrome in mice.","volume":"90","author":"Gishizky","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111908093817900_B29","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780.422k15_3780_3792","article-title":"Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow.","volume":"92","author":"Pear","year":"1998","journal-title":"Blood"},{"key":"2019111908093817900_B30","doi-asserted-by":"crossref","first-page":"10002","DOI":"10.1073\/pnas.1633833100","article-title":"Expression of BCR\/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias.","volume":"100","author":"Jaiswal","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111908093817900_B31","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1073\/pnas.97.4.1737","article-title":"Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.","volume":"97","author":"Era","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111908093817900_B32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/71691","article-title":"Reversibility of acute B-cell leukaemia induced by BCR-ABL1.","volume":"24","author":"Huettner","year":"2000","journal-title":"Nat Genet"},{"key":"2019111908093817900_B33","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.4049\/jimmunol.144.9.3602","article-title":"Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines.","volume":"144","author":"Nunez","year":"1990","journal-title":"J Immunol"},{"key":"2019111908093817900_B34","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood.V96.2.676","article-title":"Versatility of BCR\/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects.","volume":"96","author":"Salomoni","year":"2000","journal-title":"Blood"},{"key":"2019111908093817900_B35","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1073\/pnas.92.12.5287","article-title":"Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2.","volume":"92","author":"Sanchez-Garcia","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111908093817900_B36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.onc.1201490","article-title":"BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner.","volume":"16","author":"Cambier","year":"1998","journal-title":"Oncogene"},{"key":"2019111908093817900_B37","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood.V79.5.1291.1291","article-title":"bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells.","volume":"79","author":"Delia","year":"1992","journal-title":"Blood"},{"key":"2019111908093817900_B38","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000096858","article-title":"Changes in expression of apoptosis-related genes are linked to the molecular response to imatinib treatment in chronic-phase chronic myeloid leukemia patients.","volume":"117","author":"Wei","year":"2007","journal-title":"Acta Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/11\/2517\/1479788\/zh801109002517.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/11\/2517\/1479788\/zh801109002517.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T01:00:47Z","timestamp":1709946047000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/11\/2517\/110000\/Genetic-variants-in-the-candidate-genes-of-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,12]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-07-169110","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,12]]}}}